Anugerah 88 Logo
$17.60+0.14|(+0.80%)

Analyst Recommendation Trends

Wall Street analyst consensus for VTRS over the last few months:

2026-09-01
Buy: 7
S.Buy: 4
Hold: 5
Sell: 1
2026-08-01
Buy: 7
S.Buy: 4
Hold: 5
Sell: 1
2026-07-01
Buy: 7
S.Buy: 4
Hold: 5
Sell: 1
2026-06-01
Buy: 8
S.Buy: 4
Hold: 5
Sell: 1

Latest VTRS News

Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success

Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.

SeekingAlpha9/30/2026

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider, and is based on independent employee feedback collected globally, highlighting employee trust, workplace experience and organizational culture at Viatris.

Yahoo9/29/2026

Stay informed with the top movers within the S&P500 index on Monday.

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

ChartMill9/28/2026

Viatris sues Novo Nordisk over generic Wegovy patent dispute

Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.

Yahoo9/25/2026

Is Viatris Stock Outperforming the S&P 500?

Viatris has comfortably outperformed the broader S&P 500 over the past year, with analysts maintaining a fairly bullish outlook on the stock.

Yahoo9/24/2026

Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.

Benzinga9/23/2026

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

Benzinga9/23/2026

Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?

Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or pitolisant, for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction. The narcolepsy approval covers types 1 and 2, with and without cataplexy, or sudden muscle weakness. The […]

Yahoo9/21/2026

3 US Stocks That Could Gain If Buyers Shift Away From India

A new US law that could slap tariffs of up to 100% on imports from big buyers of Russian energy, including India, suddenly puts long trusted trade routes in question and opens the door for alternative suppliers. That shift creates a potential opening for US-focused stocks exposed to this news, and investors who ignore it risk missing a meaningful realignment in global sourcing. This article examines the law’s potential ripple effects and highlights 3 stocks from the screener that could be...

Yahoo9/19/2026

Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation

Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.

Yahoo9/16/2026

Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.

Benzinga9/16/2026

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo

Yahoo9/16/2026

Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today

Benzinga9/16/2026

3 Healthcare Stocks That Fall Short

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.

Yahoo9/14/2026

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Click here to read more.

SeekingAlpha9/9/2026

Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.

Benzinga9/9/2026

Argus Research Maintains Buy on Viatris, Raises Price Target to $20

Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.

Benzinga9/8/2026

Related Stocks (Peers)

Companies operating in similar sectors to VTRS:

MRKPFEBMYRPRXZTSVTRSCORTELANAXSMLLY

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-08-15Enrietti Andrew-998--
2026-08-15Enrietti Andrew-25,134--
2026-08-15Enrietti Andrew-435$16.23$7,060
2026-08-15Enrietti Andrew+999--
2026-08-15Enrietti Andrew-10,931$16.23$177,410
2026-08-15Enrietti Andrew+25,134--
2026-06-30Groothuis Leo Frans+2,756$15.88$43,765
2026-06-30SIMMONS DAVID S+2,362$15.88$37,509
2026-06-25Campbell Paul-50,076$16.1711$809,784
2026-04-15Le Goff Corinne-3,644--
2026-04-15Le Goff Corinne-39,344--
2026-04-15Le Goff Corinne-1,617$13.86$22,412
2026-04-15Le Goff Corinne+3,644--
2026-04-15Le Goff Corinne-17,450$13.86$241,857
2026-04-15Le Goff Corinne+39,344--
2026-03-23Campbell Paul-21,350$13.2805$283,539
2026-03-06Le Goff Corinne+88,984--
2026-03-06Le Goff Corinne-2,192--
2026-03-06Le Goff Corinne-44,165--
2026-03-06Le Goff Corinne-973$14.16$13,778
2026-03-06Le Goff Corinne+2,193--
2026-03-06Le Goff Corinne-19,588$14.16$277,366
2026-03-06Le Goff Corinne+44,165--
2026-03-06Mistras Theodora+86,017--
2026-03-06Mistras Theodora-2,071--
2026-03-06Mistras Theodora-41,711--
2026-03-06Mistras Theodora-1,146$14.16$16,227
2026-03-06Mistras Theodora+2,071--
2026-03-06Mistras Theodora-23,067$14.16$326,629
2026-03-06Mistras Theodora+41,711--
2026-03-06Enrietti Andrew+60,435--
2026-03-06Enrietti Andrew-952--
2026-03-06Enrietti Andrew-19,169--
2026-03-06Enrietti Andrew-415$14.16$5,876
2026-03-06Enrietti Andrew+952--
2026-03-06Enrietti Andrew-8,337$14.16$118,052
2026-03-06Enrietti Andrew+19,169--
2026-03-06Groothuis Leo Frans+15,890--
2026-03-06Groothuis Leo Frans-1,174--
2026-03-06Groothuis Leo Frans-23,660--
2026-03-06Groothuis Leo Frans-62$14.16$878
2026-03-06Groothuis Leo Frans+1,175--
2026-03-06Groothuis Leo Frans-1,243$14.16$17,601
2026-03-06Groothuis Leo Frans+23,660--
2026-03-06MARK RICHARD A+15,890--
2026-03-06MARK RICHARD A-1,174--
2026-03-06MARK RICHARD A-23,660--
2026-03-06MARK RICHARD A+1,175--
2026-03-06MARK RICHARD A+23,660--
2026-03-06Campbell Paul+56,727--
2026-03-06Campbell Paul-1,371--
2026-03-06Campbell Paul-27,603--
2026-03-06Campbell Paul-601$14.16$8,510
2026-03-06Campbell Paul+1,371--
2026-03-06Campbell Paul-12,088$14.16$171,166
2026-03-06Campbell Paul+27,603--
2026-03-06Maletta Matthew Joseph+59,323--
2026-03-06Smith Scott Andrew+256,074--
2026-03-06Smith Scott Andrew-6,181--
2026-03-06Smith Scott Andrew-124,519--
2026-03-06Smith Scott Andrew-2,433$14.16$34,451
2026-03-06Smith Scott Andrew+6,182--
2026-03-06Smith Scott Andrew-48,999$14.16$693,826
2026-03-06Smith Scott Andrew+124,519--
2026-03-06Vivaldi Coelho Rogerio+15,890--
2026-03-06Vivaldi Coelho Rogerio-1,174--
2026-03-06Vivaldi Coelho Rogerio-23,660--
2026-03-06Vivaldi Coelho Rogerio+1,175--
2026-03-06Vivaldi Coelho Rogerio+23,660--
2026-03-06SEVERINO MICHAEL+15,890--
2026-03-06SEVERINO MICHAEL-918--
2026-03-06SEVERINO MICHAEL-25,112--
2026-03-06SEVERINO MICHAEL+919--
2026-03-06SEVERINO MICHAEL+25,112--
2026-03-06Lyons Dillon JoEllen+15,890--
2026-03-06Lyons Dillon JoEllen-1,174--
2026-03-06Lyons Dillon JoEllen-23,660--
2026-03-06Lyons Dillon JoEllen+1,175--
2026-03-06Lyons Dillon JoEllen+23,660--
2026-03-06SIMMONS DAVID S+15,890--
2026-03-06SIMMONS DAVID S-523--
2026-03-06SIMMONS DAVID S-22,820--
2026-03-06SIMMONS DAVID S+524--
2026-03-06SIMMONS DAVID S+22,820--
2026-03-06PARRISH MARK W+15,890--
2026-03-06PARRISH MARK W-1,174--
2026-03-06PARRISH MARK W-23,660--
2026-03-06PARRISH MARK W+1,175--
2026-03-06PARRISH MARK W+23,660--
2026-03-06FINNEY ELISHA W+15,890--
2026-03-06FINNEY ELISHA W-1,174--
2026-03-06FINNEY ELISHA W-23,660--
2026-03-06FINNEY ELISHA W+1,175--
2026-03-06FINNEY ELISHA W+23,660--
2026-03-06DAMELIO FRANK A+15,890--
2026-03-06DAMELIO FRANK A-918--
2026-03-06DAMELIO FRANK A-25,112--
2026-03-06DAMELIO FRANK A+919--
2026-03-06DAMELIO FRANK A+25,112--
2026-03-06CORNWELL W DON+15,890--
2026-03-06CORNWELL W DON-1,174--
2026-03-06CORNWELL W DON-23,660--
2026-03-06CORNWELL W DON+1,175--
2026-03-06CORNWELL W DON+23,660--
2026-03-06HIGGINS MELINA E+15,890--
2026-03-06HIGGINS MELINA E-1,174--
2026-03-06HIGGINS MELINA E-23,660--
2026-03-06HIGGINS MELINA E+1,175--
2026-03-06HIGGINS MELINA E+23,660--
2026-03-06KILTS JAMES M+15,890--
2026-03-06KILTS JAMES M-1,174--
2026-03-06KILTS JAMES M-23,660--
2026-03-06KILTS JAMES M+1,175--
2026-03-06KILTS JAMES M+23,660--
2026-03-04Mistras Theodora-2,935--
2026-03-04Mistras Theodora-31,149--
2026-03-04Mistras Theodora-1,624$14.71$23,889
2026-03-04Mistras Theodora+2,935--
2026-03-04Mistras Theodora-17,226$14.71$253,394
2026-03-04Mistras Theodora+31,149--
2026-03-04Le Goff Corinne-3,053--
2026-03-04Le Goff Corinne-36,720--
2026-03-04Le Goff Corinne-1,355$14.71$19,932
2026-03-04Le Goff Corinne+3,053--
2026-03-04Le Goff Corinne-16,300$14.71$239,773
2026-03-04Le Goff Corinne+36,720--
2026-03-04Enrietti Andrew-1,278--
2026-03-04Enrietti Andrew-13,568--
2026-03-04Enrietti Andrew-557$14.71$8,193
2026-03-04Enrietti Andrew+1,279--
2026-03-04Enrietti Andrew-5,901$14.71$86,804
2026-03-04Enrietti Andrew+13,568--
2026-03-04Campbell Paul-1,612--
2026-03-04Campbell Paul-17,108--
2026-03-04Campbell Paul-706$14.71$10,385
2026-03-04Campbell Paul+1,612--
2026-03-04Campbell Paul-7,492$14.71$110,207
2026-03-04Campbell Paul+17,108--
2026-03-04Smith Scott Andrew-8,714--
2026-03-04Smith Scott Andrew-92,503--
2026-03-04Smith Scott Andrew-3,429$14.71$50,441
2026-03-04Smith Scott Andrew+8,714--
2026-03-04Smith Scott Andrew-36,400$14.71$535,444
2026-03-04Smith Scott Andrew+92,503--
2026-03-03Enrietti Andrew-110,630--
2026-03-03Enrietti Andrew+110,630--
2026-03-03Enrietti Andrew-1,708--
2026-03-03Enrietti Andrew-11,531--
2026-03-03Enrietti Andrew-48,113$14.89$716,403
2026-03-03Enrietti Andrew+110,630--
2026-03-03Enrietti Andrew-744$14.89$11,078
2026-03-03Enrietti Andrew+1,709--
2026-03-03Enrietti Andrew-5,094$14.89$75,850
2026-03-03Enrietti Andrew+11,531--
2026-03-03Campbell Paul-169,718--
2026-03-03Campbell Paul+169,718--
2026-03-03Campbell Paul-2,619--
2026-03-03Campbell Paul-17,689--
2026-03-03Campbell Paul-74,320$14.89$1,106,625
2026-03-03Campbell Paul+169,718--
2026-03-03Campbell Paul-1,148$14.89$17,094
2026-03-03Campbell Paul+2,620--
2026-03-03Campbell Paul-7,868$14.89$117,155
2026-03-03Campbell Paul+17,689--
2026-03-03Smith Scott Andrew-1,286,849--
2026-03-03Smith Scott Andrew+1,286,849--
2026-03-03Smith Scott Andrew-18,153--
2026-03-03Smith Scott Andrew-135,828--
2026-03-03Smith Scott Andrew-506,376$14.89$7,539,939
2026-03-03Smith Scott Andrew+1,286,849--
2026-03-03Smith Scott Andrew-7,144$14.89$106,374
2026-03-03Smith Scott Andrew+18,154--
2026-03-03Smith Scott Andrew-53,449$14.89$795,856
2026-03-03Smith Scott Andrew+135,828--
2026-01-01Mistras Theodora-2,175--
2026-01-01Mistras Theodora-23,085--
2026-01-01Mistras Theodora-1,203$12.45$14,977
2026-01-01Mistras Theodora+2,175--
2026-01-01Mistras Theodora-13,395$12.45$166,768
2026-01-01Mistras Theodora+23,085--
2025-11-03SIMMONS DAVID S+213$10.4255$2,221